Navigation Links
Soligenix Announces Expansion of Partnership With Sigma-Tau Pharmaceuticals for orBec® in Europe
Date:7/28/2011

er clinical trial conducted at the Fred Hutchinson Cancer Research Center, which demonstrated statistical significance in its primary endpoint of controlling GI GVHD (p-value 0.02). The second study was a 129-patient pivotal Phase 3 multi-center clinical trial conducted at 16 leading bone marrow/stem cell transplant centers in the US and France. Although orBec® did not achieve statistical significance in the primary endpoint of its pivotal trial, namely median time-to-treatment failure through Day 50 (p-value 0.1177), orBec® did achieve statistical significance in other key secondary endpoints such as the proportion of patients free of GVHD at Day 50 (p-value 0.05) and Day 80 (p-value 0.005) and the median time to treatment failure through Day 80 (p-value 0.0226), as well as a 66% reduction in mortality among patients randomized to orBec® at 200 days post-transplant with only 5 patient (8%) deaths in the orBec® group compared to 16 patient (24%) deaths in the placebo group (p-value 0.0139).  At one year post-randomization in the Phase 3 trial, 18 patients (29%) in the orBec® group and 28 patients (42%) in the placebo group died within one year of randomization (46% reduction in mortality, p-value 0.04).

orBec® represents a first-of-its-kind oral, locally acting therapy tailored to treat the GI manifestation of acute GVHD, the organ system where GVHD is most frequently encountered and highly problematic.  orBec® is intended to reduce the need for systemic immunosuppressive drugs to treat GI GVHD.  orBec® is formulated for oral administration in GVHD patients as a single product consisting of two tablets; one tablet is intended to release BDP in the proximal portions of the GI tract, and the other tablet is intended to release BDP in the distal portions of the GI tract.  Oral BDP may also have application in treating other GI disorders characterized by severe inflammation.  

In addition to
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Soligenix Announces Appointment of Jerome Zeldis, MD, PhD and Keith Brownlie, CPA to its Board of Directors
2. Soligenix Appoints Joseph Warusz as Vice President of Administration and Controller
3. Soligenix to Present at 13th Annual BIO CEO & Investor Conference
4. Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer
5. Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
6. Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury
7. Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
8. Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
9. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
10. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
11. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: UPI ... markets innovative proprietary products to treat voiding dysfunctions, today ... ROTH Conference on Tuesday, March 10, 2015. Rob ... , Chief Financial Officer, will present at 4:00 p.m. ... at the conference at the Ritz Carlton in ...
(Date:2/26/2015)... -- Finesse expands office in Leicester, United Kingdom ... of its operations in Leicester , ... for customers is expected shortly afterward. With ... the current office, the new premises will double the ... Finesse to bring on more service personnel. The new ...
(Date:2/26/2015)... , Feb. 26, 2015  Today the ... The psychological and physical side effects of pain ... opioid painkillers, such as Vicodin and Oxycontin, are safer ... Americans overdose on prescription painkillers than on heroin and ... and CEO of NSC. "Yet, these medications are marketed ...
Breaking Medicine Technology:Uroplasty to Participate in the 27th Annual ROTH Conference 2New Finesse Office in United Kingdom 2National Safety Council: Opioid prescription painkillers have hidden, deadly side effects 2
... NEW YORK, Oct. 1 Keryx Biopharmaceuticals,Inc. (Nasdaq: ... the,Company,s President, will present an overview of the Company,s ... Growth Stock,Conference in New York City. Dr. Henderson,s presentation ... ET. Dr. Henderson,s presentation will be webcast live ...
... -Two 48-week Superiority Studies versus Hepsera(R) in Patients with Chronic ... Hepatitis B-,-Studies will also Assess Clevudine,s ... ... Pharmasset, Inc.,(Nasdaq: VRUS ) has commenced dosing in Phase 3 registration clinical trials,of clevudine ...
Cached Medicine Technology:Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference 2Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 2Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 3Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 4Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 5
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 ... to innovative thinking. “The #1 block was lack ... tools,” reports Haman, who created the Thinkubator Innovation Studio ... felt that they did not have enough time for ... to stimulate innovation. , Solutionman’s monthly “Accelerating Innovation Training” ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 March—also ... good time to remind ourselves and others that ... say Atlantic NeuroSurgical Specialists (ANS). , Concussions are ... account for 75% of TBIs. There are 1.6-3.8 ... may sound benign, but it is a brain ...
(Date:2/28/2015)... 2015 A study out of the ... therapy procedure for the treatment of a hereditary ocular ... Authored by Dr. Robert MacLaren, professor of ophthalmology ... Lancet Medical Journal on January 16, 2014 , the ... genetic disorder that mostly affects men and leads to ...
(Date:2/28/2015)... February 28, 2015 National ... outsourced sales, marketing and supply chain management for ... Botanicals, is bringing its award winning solutions for ... Botanicals’ products are specifically created to combat thinning-damaged ... BIOTA is committed to marrying science with nature ...
(Date:2/28/2015)... AZ (PRWEB) February 28, 2015 Kaylie ... and alcohol treatment center , and current student obtaining ... University, has implemented a weekly forum in psychoeducation on ... school in Flagstaff, AZ as part of her studies. ... big need for support and counseling at the high ...
Breaking Medicine News(10 mins):Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2
... test the drug manufactured by German pharmaceutical company TeGenero by ... which was designed to treat rheumatoid arthritis, leukaemia and multiple ... six men who fell seriously ill after taking part in ... like his brain was on fire. Student Nav Modi, 24, ...
... suggests that thinking that you are strong and muscles are ... Hull University research team which asked 30 subjects to do ... focused on what the muscles were doing. ,The ... which monitored levels of electrical activity in their biceps and ...
... a news study it has been shown that babies who ... have the much feared consequences and is safe. The way ... theory was researched and assessed by unconnected Nottingham researchers to ... was pioneered by controversial Stoke-based paediatrician Professor David Southall. ...
... alcohol intake seems to question the earlier studies that ... drinkers, as compared to abstainers or heavy drinkers. ... mistake in the perception of who “abstainers” are, when ... PhD, emerita professor at the University of California, San ...
... 7-day old baby was charred to death due to a short ... their joy and hopes. The incubator in which the baby was ... incident had happened due to negligence of the hospital staff while ... were saved due to prompt action of the medical staff who ...
... to the tune of ?4m or more will be allocated ... spending should take care of containing// the unhealthy trend, atleast ... up by almost 50%. ,A senior medical post ... with suicidal tendencies, according to Mr Woodward. To enable this ...
Cached Medicine News:Health News:High Spirits :Second Thoughts on the Mini Pegs 2Health News:The Face Of Indian Health Care: A World Health Day Evaluation 2Health News:The Face Of Indian Health Care: A World Health Day Evaluation 3Health News:The Face Of Indian Health Care: A World Health Day Evaluation 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: